Antibiotic Treatment Pipeline for Clostridioides difficile Infection (CDI): A Wide Array of Narrow-Spectrum Agents

T. J. Carlson, A. J. Gonzales-Luna

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Purpose of Review: Clostridioides difficile infection (CDI) represents a major burden on the U.S. healthcare system. Despite the U.S. Food and Drug Administration (FDA) approval of fidaxomicin in 2011, observed rates of clinical cure and CDI recurrence suggest there is room to improve. As a result, there are many antibiotic treatments in the developmental pipeline for CDI. The purpose of this focused review is to summarize these antibiotic therapies in all stages of development. Recent Findings: Here, we discuss 10 antibiotics in development, including three that have completed phase II trials, five in phase II trials, and two still undergoing preclinical trials. Summary: The antibiotic treatment pipeline for CDI contains a plethora of narrow-spectrum agents with unique mechanisms of action and potent activity against C. difficile. Only ridinilazole, LFF571, and ramoplanin have completed phase II trials, and ridinilazole is the only antibiotic to begin recruitment for a phase III trial. While the future of CDI treatment appears bright, the healthcare community will have to await the results from phase III trials.

Original languageEnglish (US)
Article number20
JournalCurrent Infectious Disease Reports
Issue number8
StatePublished - Aug 1 2020
Externally publishedYes


  • Antibiotic
  • Clinical trial
  • Clostridium difficile
  • Drug pipeline
  • Microbiome
  • Narrow spectrum

ASJC Scopus subject areas

  • Infectious Diseases


Dive into the research topics of 'Antibiotic Treatment Pipeline for Clostridioides difficile Infection (CDI): A Wide Array of Narrow-Spectrum Agents'. Together they form a unique fingerprint.

Cite this